Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 10:40 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1465–1488 of 16,128 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Skin Disorder Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects

NCT01287858
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
AC430
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 2, 2015 · Synced Nov 3, 2026, 10:40 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Androgenetic Alopecia in Fabry Disease

NCT01295008
View directory record Official record
Conditions
Fabry Disease
Interventions
Not listed
Lead sponsor
Baylor Research Institute
Other
Eligibility
18 Years to 64 Years · Male only
Enrollment
107 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 2 Interventional Results available

Study of rADAMTS-13 (SHP655) in the Treatment of Participants With Acquired Thrombotic Thrombocytopenic Purpura (aTTP)

NCT03922308
View directory record Official record
Conditions
Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
Interventions
Placebo, SHP655, Standard of Care
Other · Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years to 75 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
7
States / cities
Birmingham, Alabama • Boston, Massachusetts • Minneapolis, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2022 · Synced Nov 3, 2026, 10:40 AM EST
Terminated No phase listed Observational

Evaluation of Mammographic Breast Density in Participants with Hormone Receptor-Negative Breast Cancer Enrolled on Study A011502

NCT03609021
View directory record Official record
Conditions
Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative
Interventions
Screening Mammography, Biospecimen Collection
Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Female only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
514
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Glendale, Arizona + 341 more
Source: ClinicalTrials.gov public record
Updated Jan 16, 2025 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 2 Interventional Results available

Short-incubation Levulan Photodynamic Therapy Versus Vehicle for Face/Scalp Actinic Keratosis (AK)

NCT01475955
View directory record Official record
Conditions
Actinic Keratosis
Interventions
Broad Area ALA 1-hour incubation, Broad Area ALA 2 hour incubation, broad area ALA 3-hour incubation, Spot ALA 2 hour incubation, Vehicle PDT, Blue Light Treatment
Drug · Device
Lead sponsor
DUSA Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
235 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2016 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 1 Interventional Results available

Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma

NCT03229278
View directory record Official record
Conditions
Lymphoma, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Cancer, Recurrent Bladder Carcinoma, Recurrent Classical Hodgkin Lymphoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Renal Cell Carcinoma, Stage III Bladder Cancer, Stage III Lymphoma, Stage III Non-Small Cell Lung Cancer AJCC v7, Stage III Renal Cell Cancer, Stage III Skin Melanoma, Stage IIIA Non-Small Cell Lung Cancer AJCC v7, Stage IIIA Skin Melanoma, Stage IIIB Non-Small Cell Lung Cancer AJCC v7, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma, Stage IV Bladder Cancer, Stage IV Lymphoma, Stage IV Non-Small Cell Lung Cancer AJCC v7, Stage IV Renal Cell Cancer, Stage IV Skin Melanoma, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Solid Neoplasm
Interventions
Enzyme Inhibitor Therapy, Laboratory Biomarker Analysis, Nivolumab, Pembrolizumab
Drug · Other · Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 6, 2023 · Synced Nov 3, 2026, 10:40 AM EST
Active, not recruiting Phase 2 Interventional

ATI-045 Versus Placebo in Patients With Moderate-to-Severe Atopic Dermatitis

NCT07011706
View directory record Official record
Conditions
Atopic Dermatitis, Atopic, Dermatitis, AD, Eczema
Interventions
ATI-045, Placebo
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
53
States / cities
Phoenix, Arizona • Tucson, Arizona • Bryant, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Completed No phase listed Observational

Bone Health in Patients With Atopic Dermatitis

NCT03800004
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
5 Years to 17 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Nov 3, 2026, 10:40 AM EST
Terminated Phase 2 Interventional Results available

Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma

NCT02831933
View directory record Official record
Conditions
Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma
Interventions
ADV/HSV-tk, Valacyclovir, SBRT, nivolumab
Biological · Drug · Radiation
Lead sponsor
Eric Bernicker, MD
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2023 · Synced Nov 3, 2026, 10:40 AM EST
Not yet recruiting Early Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Distribution of 64Cu/68Ga Labeled CM500 in Healthy Volunteers and Patients With Cancer

NCT07781852
View directory record Official record
Conditions
Bladder Cancer, Glioma, Glioblastoma (GBM), Breast Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pharynx Cancer, Oral Cavity Cancer, Kidney Cancer, Liver Cancer, Lung Cancer (NSCLC), Ovarian Cancer, Pancreatic Cancer, PDAC - Pancreatic Ductal Adenocarcinoma, Prostate Cancer
Interventions
[64Cu]CM500, [68Ga]CM500, PET/MR, PET/CT, Blood Collection
Drug · Device · Procedure
Lead sponsor
Lumina Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
3
States / cities
Boston, Massachusetts • Grand Rapids, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

NCT03400215
View directory record Official record
Conditions
Breast Cancer
Interventions
Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Recruiting Not applicable Interventional

Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer

NCT05042687
View directory record Official record
Conditions
Breast Cancer
Interventions
Tc99m sestamibi
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Completed No phase listed Observational

A Natural History Study of Biomarkers and Clinical Outcomes in Mucopolysaccharidosis Type IIIA (MPS IIIA; Sanfilippo Syndrome)

NCT05523206
View directory record Official record
Conditions
Mucopolysaccharidosis III-A
Interventions
No intervention
Other
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
4 Months to 13 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2025 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 4 Interventional

Letrozole in Treating Postmenopausal Women With Metastatic Breast Cancer

NCT00014638
View directory record Official record
Conditions
Breast Cancer
Interventions
letrozole
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
20
States / cities
Berkeley, California • Long Beach, California • Hollywood, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Nov 3, 2026, 10:40 AM EST
Active, not recruiting Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.

NCT04157348
View directory record Official record
Conditions
Eosinophilic Granulomatous Vasculitis
Interventions
Benralizumab, Mepolizumab, Placebo to Mepolizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Denver, Colorado • Ann Arbor, Michigan • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 1 Interventional Results available

PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery

NCT03218826
View directory record Official record
Conditions
Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Prostate Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Prostate Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma, Unresectable Solid Neoplasm
Interventions
Docetaxel, Laboratory Biomarker Analysis, Pharmacological Study, PI3Kbeta Inhibitor AZD8186
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
8
States / cities
Aurora, Colorado • Baltimore, Maryland • Bethesda, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Active, not recruiting No phase listed Observational

HEAL-4: Real-World Effectiveness of 4 Amniotic Allografts Adjunctive to Standard Care in DFU, VLU, and PU

NCT07223515
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU), Venous Leg Ulcers (VLUs), Pressure Ulcers, Bedsores, Decubitus Ulcer
Interventions
Not listed
Lead sponsor
Dynamic Medical Services dba Acesso Biologics
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
2
States / cities
Novi, Michigan • Murfreesboro, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 3 Interventional Results available

Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne

NCT02320149
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Sarecycline, Placebo
Drug
Lead sponsor
Almirall, S.A.
Industry
Eligibility
9 Years to 45 Years
Enrollment
968 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Beverly Hills, California • Encino, California • La Mesa, California + 50 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Nov 3, 2026, 10:40 AM EST
Completed Not applicable Interventional

MBC Physical Activity Study

NCT06500858
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma
Interventions
Exercise Intervention, Health Promotion and Education, Internet-Based Intervention, Physical Activity, Questionnaire Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Nov 3, 2026, 10:40 AM EST
Active, not recruiting Phase 1 Interventional

Study to Evaluate the Safety of Colchicine

NCT05335148
View directory record Official record
Conditions
Radiation Therapy
Interventions
oral colchicine(0.6 mg) once a day
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Livingston, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 2 Interventional Results available

A Dose-Ranging Study of the Effect of Glycopyrrolate in Subjects With Axillary Hyperhidrosis

NCT02016885
View directory record Official record
Conditions
Hyperhidrosis
Interventions
glycopyrrolate, 1.0%, glycopyrrolate, 2.0%, glycopyrrolate, 3.0%, glycopyrrolate, 4.0%, Vehicle
Drug · Other
Lead sponsor
Journey Medical Corporation
Industry
Eligibility
18 Years and older
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
21
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Encinitas, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Nov 3, 2026, 10:40 AM EST
Terminated Phase 1Phase 2 Interventional Results available

A Clinical Trial Assessing Efficacy and Safety of Sunitinib and Exemestane in Patients With ER [Estrogen Receptor] + and/or PgR [Progesterone Receptor] + Breast Cancer

NCT00417885
View directory record Official record
Conditions
Breast Neoplasms
Interventions
exemestane, sunitinib malate
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 21, 2010 · Synced Nov 3, 2026, 10:40 AM EST
Active, not recruiting Phase 2 Interventional

A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies

NCT05885555
View directory record Official record
Conditions
Primary Immune Thrombocytopenia (ITP)
Interventions
Ianalumab
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Nov 3, 2026, 10:40 AM EST
Completed Phase 3 Interventional Results available

Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)

NCT00605176
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, Placebo
Drug
Lead sponsor
Graceway Pharmaceuticals, LLC
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Fremont, California • Los Angeles, California • Riverside, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2010 · Synced Nov 3, 2026, 10:40 AM EST